

11 September 2024

Eye Co Wins Ethics Approval for Efficacy Study in dry AMD

Eye Co wins ethics approval for a **Phase II**, Multicentre, 2-part, Study of the Safety, Tolerability, and Efficacy of Intravitreal **ALVIZON** (fludrocortisone acetate) in Geographic Atrophy (GA) secondary to dry-AMD.

ALVIZON is a novel therapeutic agent which has been shown to improve retinal function in numerous clinical and pre-clinical studies of dry-AMD without significant side-effects or IOP rise.

The first stage of the Phase II study will get underway in early October 2024 and patients will receive two treatments at three monthly intervals.

Outcome measures include change in **visual acuity** providing an early indication of potential efficacy.

ALVIZON is a potent mineralocorticoid producing an intraocular anti-inflammatory effect without the common side effects of raised intraocular pressure and cataract development.

Only very limited treatment options currently exist for this debilitating disease, none of which demonstrated improvement of visual acuity, and all associated with significant side effects. None of these treatments are currently approved in Australia.

This clearance by the independent Ethics Committee demonstrates the potential for **ALVIZON**.